Pfizer’s Sutent Outperforms Conventional Therapy For First-Line Renal Cell Carcinoma
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase III study of sunitinib reports significant improvement in first-line use.
You may also be interested in...
Pfizer's Sutent Receives Dual Approvals For Kidney Cancer & Stomach Cancer
Pfizer's Sutent received accelerated approval for first-line treatment of advanced renal cell carcinoma and full approval for treatment of refractory gastrointestinal stromal tumors.
Bayer/Onyx’ Nexavar Approved For Kidney Cancer
FDA’s full approval of the oncologic indicates sorafenib for broad use by all patients with advanced renal cell carcinoma.
India Highlights "Public Interest" To Reign In Prices For Non-Scheduled Drugs
Dr. Reddy's, GSK, Ranbaxy and UCB among manufacturers that could see prices reduced under government order that reflects issues raised in Gleevec patent dispute.